JD
John F. Dipersio
Highly rated in
43
conditions
Highly rated in
43
conditions
Check Dr. John F. Dipersio's experience treating your condition:
About Dr. John F. Dipersio

John Dipersio is an Oncologist and a Hematologist Oncology expert in Saint Louis, Missouri. Dipersio has been practicing medicine for over 42 years and is highly rated in 43 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Acute Myeloblastic Leukemia with Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration. He is licensed to treat patients in Missouri. Dipersio is currently accepting new patients.

His clinical research consists of co-authoring 310 peer reviewed articles and participating in 55 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. John F. Dipersio it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. John F. Dipersio accepts the following insurance:

  •  Ambetter
  •  Cigna
  •  Cox Health

Call to see if your plan is accepted.
Locations
4921 Parkview Pl, Saint Louis, MO 63110
Other Locations
4921 Parkview Pl, 7th Floor, Saint Louis, MO 63110
660 S Euclid Ave, Saint Louis, MO 63110
Background & Education
Graduate Institution
University Of Rochester School Of Medicine And Dentistry, 1980
Specialties
Oncology
Hematology Oncology
Licenses
Internal Medicine in MO
Hospital Affiliations
Cox Medical Center South
Barnes-Jewish Hospital
Barnes-Jewish St Peters Hospital
Jacksonville Memorial Hospital
Barnes-Jewish West County Hospital
Springfield Memorial Hospital
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


53 Clinical Trials

Identification of AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration
A Phase Ib Study of Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease
Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance
A Phase I/II Trial of Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma
Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant in Children and Adults
A Long-term Follow-up Study of Patients Who Received VOR33
Phase II Trial With Safety Lead in of Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas
A Phase II Study of Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation
Effect of rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temzolomide
Phase I Dose Escalation and Dose Expansion Study of Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy
Open Label, Phase II Dosing Study of Ara-C Chemotherapy in Combination With EL625 and Idarubicin in Refractory and Relapsed Acute Myelogenous Leukemia (AML)
Phase I/II Trial of Intravenous Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation
A Phase I/II Study of Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation
A Single-Arm, Open-Label Phase I Clinical Trial of a JAK Inhibitor, Baricitinib, for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation
A Phase 1/2 Study of Cytokine-Induced Memory-Like NK Cells in Patients With AML or MDS
Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus Conventional Treatment for Treating Steroid Resistant Acute Graft-versus Host Disease
A Pilot Study of Ruxolitinib to Combat COVID-19
A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma
Infusion of Genetically Modified T Cells: A Pilot Study of Tracking and Toxicity
An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
A Phase 2 Study of Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS
A Multi-Center Phase 2 Study of Combined Modality Treatment With Ruxolitinib, Decitabine, and Donor Lymphocyte Infusion for Post-Transplant Relapse of AML or MDS
A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
A Phase 2 Study of Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed AML
Pilot Study of a Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma
Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma: a Pilot Feasibility Study Using a Novel Protocol
A Pilot Study of Belimumab (Benlysta) for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation
A Pilot Study of Pacritinib in Combination With Low Dose Decitabine in Patients With Intermediate-High Risk Myelofibrosis or MPN/MDS Syndromes
A Phase I/II Trial of Infusional Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia
A Pilot Study of Myeloablative Allogeneic or Haploidentical Stem Cell Transplantation With High Dose PT-Cy in Relapsed/Refractory AML
A Pilot Study of Duvelisib to Combat COVID-19
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
An Investigator Sponsored Phase I/II Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia
View 36 Less Clinical Trials -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors